80 related articles for article (PubMed ID: 10725546)
1. Fusion of uninfected T-cells occurs with immature HIV-1 protease-mutant, but not morphologically similar protease inhibitor derived particles.
Bahmani MK; Kameoka M; Goto T; Sano K; Luftig RB; Ikuta K
Virus Res; 2000 Feb; 66(2):131-7. PubMed ID: 10725546
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of human immunodeficiency virus type 1 infectivity by replacing the region including Env derived from defective particles with an ability to form particle-mediated syncytia in CD4+T cells.
Kinomoto M; Mukai T; Li YG; Iwabu Y; Warachit J; Palacios JA; Ibrahim MS; Tsuji S; Goto T; Ikuta K
Microbes Infect; 2004 Aug; 6(10):911-8. PubMed ID: 15310467
[TBL] [Abstract][Full Text] [Related]
3. Protease-defective, gp120-containing human immunodeficiency virus type 1 particles induce apoptosis more efficiently than does wild-type virus or recombinant gp120 protein in healthy donor-derived peripheral blood T cells.
Kameoka M; Kimura T; Zheng YH; Suzuki S; Fujinaga K; Luftig RB; Ikuta K
J Clin Microbiol; 1997 Jan; 35(1):41-7. PubMed ID: 8968878
[TBL] [Abstract][Full Text] [Related]
4. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells.
Goto T; Nakano T; Kohno T; Morimatsu S; Morita C; Hong W; Kiso Y; Nakai M; Sano K
J Med Virol; 2001 Mar; 63(3):203-9. PubMed ID: 11170058
[TBL] [Abstract][Full Text] [Related]
5. Production of doughnut-shaped, protease-defective particles from a human T cell clone carrying a provirus with specific mutations in the env, pol, vpr, and nef genes.
Bahmani MK; Kameoka M; Nakaya T; Fujinaga K; Zhong Q; Takahashi H; Nakano T; Nakai M; Ueda S; Jones IM; Luftig RB; Ikuta K
AIDS Res Hum Retroviruses; 1997 Apr; 13(6):523-6. PubMed ID: 9100995
[No Abstract] [Full Text] [Related]
6. Noninfectious doughnut-shaped human immunodeficiency virus type 1 can induce syncytia mediated by fusion of the particles with CD4-positive cells.
Ohki K; Kishi Y; Nishino Y; Sumiya M; Kimura T; Goto T; Nakai M; Ikuta K
J Acquir Immune Defic Syndr (1988); 1991; 4(12):1233-40. PubMed ID: 1682474
[TBL] [Abstract][Full Text] [Related]
7. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins.
Cherry E; Liang C; Rong L; Quan Y; Inouye P; Li X; Morin N; Kotler M; Wainberg MA
J Mol Biol; 1998 Nov; 284(1):43-56. PubMed ID: 9811541
[TBL] [Abstract][Full Text] [Related]
8. Superinfection of human immunodeficiency virus type 1 (HIV-1) to cell clone persistently infected with defective virus induces production of highly cytopathogenic HIV-1.
Iwabu Y; Goto T; Tsuji S; Warachit J; Li GM; Shoji S; Kameoka M; Ikuta K
Microbes Infect; 2006 Jun; 8(7):1773-82. PubMed ID: 16815724
[TBL] [Abstract][Full Text] [Related]
9. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.
Kräusslich HG; Ochsenbauer C; Traenckner AM; Mergener K; Fäcke M; Gelderblom HR; Bosch V
Virology; 1993 Feb; 192(2):605-17. PubMed ID: 8421902
[TBL] [Abstract][Full Text] [Related]
10. Control of human immunodeficiency virus type-1 protease activity in insect cells expressing Gag-Pol rescues assembly of immature but not mature virus-like particles.
Adamson CS; Nermut M; Jones IM
Virology; 2003 Mar; 308(1):157-65. PubMed ID: 12706099
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes.
Balzarini J; Van Herrewege Y; Vermeire K; Vanham G; Schols D
Mol Pharmacol; 2007 Jan; 71(1):3-11. PubMed ID: 17056872
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
[TBL] [Abstract][Full Text] [Related]
14. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
[No Abstract] [Full Text] [Related]
15. HIV-1 drug resistance in newly infected individuals.
Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Davis DA; Brown CA; Singer KE; Wang V; Kaufman J; Stahl SJ; Wingfield P; Maeda K; Harada S; Yoshimura K; Kosalaraksa P; Mitsuya H; Yarchoan R
Antiviral Res; 2006 Nov; 72(2):89-99. PubMed ID: 16687179
[TBL] [Abstract][Full Text] [Related]
18. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.
Romano L; Venturi G; Giomi S; Pippi L; Valensin PE; Zazzi M
J Med Virol; 2002 Feb; 66(2):143-50. PubMed ID: 11782921
[TBL] [Abstract][Full Text] [Related]
19. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
[TBL] [Abstract][Full Text] [Related]
20. Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection.
Hattori T; Koito A; Takatsuki K; Kido H; Katunuma N
FEBS Lett; 1989 May; 248(1-2):48-52. PubMed ID: 2470618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
